Pharma & NBFCs Lead Quarter-End Rally as Institutional Rebalancing Boosts Sentiment

Defensive buying and US FDA tailwinds lift pharma; credit-growth optimism and book-dressing drive NBFC strength on the last trading day of June amid elevated quarter-end volumes.

bt-corporate · 6/30/2026, 9:04:32 AM · Ask about this →